13 results about "Peritonitis" patented technology

This invention provides a saRNA vaccine for the prevention of feline infectious peritonitis (FIP). The saRNA vaccine is a composition comprising saRNA A and saRNA B. The assembly elements of the saRNA include: a 5′ UTR, replicases nsp1-nsp4, a subgenomic promoter, a Kozak sequence, nucleic acid sequence A or nucleic acid sequence B, a 3′ UTR, and a polyadenylated tail (polyA). The saRNA vaccine provided by this invention is effective for the immunization prophylaxis of FIP types I and II. Furthermore, based on the development of this vaccine, by replacing the coding sequences of different antigens, it can be extended to the development of vaccines for other coronaviruses or other veterinary pathogens, demonstrating significant technological transfer value and industrialization prospects.

The present application relates to the field of medical devices, and discloses a peritoneal dialysis patient peritonitis early warning device based on microfluidic technology, comprising a peritoneal dialysis external catheter and a microfluidic detection module; the peritoneal dialysis external catheter comprises a main passage for dialysis liquid infusion or dialysis waste liquid drainage, and a detection branch selectively communicated with the main passage; a flow path switching structure is arranged on the peritoneal dialysis external catheter, and the flow path switching structure is used for switching between a normal state and a detection state. In the present application, the detection branch selectively communicated with the main passage is arranged on the peritoneal dialysis external catheter, and the flow path switching structure is used for switching between the normal state and the detection state, so that the dialysis waste liquid can enter the microfluidic detection module for detection while maintaining the drainage of the main passage, in-situ detection is realized without changing the basic operation process of peritoneal dialysis, and good clinical process compatibility is achieved.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

This application provides a selective HDAC6 inhibitor, its preparation method, and its application, belonging to the field of medicinal chemistry. The selective HDAC6 inhibitor is a compound of Formula I or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, and L are as described herein. The compound of Formula I is a highly selective histone deacetylase 6 (HDAC6) inhibitor, which can be used for diseases caused by HDAC6 abnormalities, such as inflammatory diseases (e.g., peritonitis, inflammatory bowel disease, psoriasis) and other diseases.

This disclosure relates to the development of a multi-antigen mRNA vaccine against feline infectious peritonitis virus (FIPV). Provided is a pharmaceutical formulation. The pharmaceutical formulation includes a nucleic acid fragment. The nucleic acid fragment is mRNA and includes at least one of a first nucleic acid fragment, a second nucleic acid fragment, or a third nucleic acid fragment. The first nucleic acid fragment encodes an M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes an S protein, an S_ec protein, or an SII protein of feline infectious peritonitis virus; and the first nucleic acid fragment, the second nucleic acid fragment, and the third nucleic acid fragment are linked or not linked.

The embodiment of the application discloses a natural small molecule inhibitor targeting NLRP3 inflammasome and application thereof, and belongs to the technical field of biological medicine. Chuanxiongdiolide R11 is a phthalide dimer compound with clear stereochemistry found in traditional Chinese medicine Chuanxiong, which can target NLRP3 inflammasome, prevent the activation and assembly of the inflammasome, thereby inhibiting caspase-1 activation, GSDMD cleavage, pyroptosis and the maturation and release of IL-1beta / IL-18. The compound can be used for preparing a drug for treating NLRP3 related inflammatory diseases such as systemic inflammation and peritonitis, and has a good clinical application prospect, and provides a new idea for developing and applying NLRP3 inhibitors in clinic.

Peritonitis sensors, including peritonitis sensors for automated peritoneal dialysis (APD) systems, and associated systems, devices, and methods are disclosed herein. In one embodiment, an APD system includes a disposable set, a portion of which is at least partially aligned with a peritonitis sensor. The peritonitis sensor can be configured to capture one or more peritonitis measurements from the solution in the disposable set. The APD system can determine whether one or more peritonitis measurements indicate the presence of peritonitis in a patient from which the solution is drained. In some embodiments, if the APD system determines that one or more peritonitis measurements indicate peritonitis, the APD system can alert a user of the system to the presence of peritonitis in the patient.

The application relates to a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof, relates to the technical field of biology, and aims to provide a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown in a sequence table SEQ ID NO.1, and the amino acid sequence of a light chain variable region is shown in a sequence table SEQ ID NO.2.The application adopts Western blot and IFA methods to identify the reactivity of MAb, and identifies an antigen epitope recognized by MAb.The antigen epitope is conservative in type I cat coronavirus, which indicates that the monoclonal antibody can recognize various type I FCoV strains, has broad spectrum, and is not accidentally directed to a single strain.The antigen epitope has no cross reaction with type II, which indicates that the specificity is high, can be used for distinguishing type I and type II infections, and has diagnostic application value.

This invention belongs to the field of biomedicine, specifically relating to a secretory self-assembling nanoparticle mRNA vaccine for feline infectious peritonitis and its application. First, this invention constructs a Ferritin fusion antigen by fusing the RBD or S1 fragment of the FIPV S protein with ferritin. Second, this invention constructs an mRNA encoding the aforementioned Ferritin fusion antigen. The mRNA is delivered into host cells via lipid nanoparticles (LNPs), where it is translated and expressed in the cytoplasm. The Ferritin fusion antigen then forms a nanoparticle structure within the cell using its natural self-assembly properties, eliminating the need for in vitro assembly steps. Compared to traditional nanoparticle vaccines, this method avoids steps such as in vitro induction expression, purification, and adjuvant addition, simplifying the production process, improving immunogenicity, reducing the risk of adverse drug reactions (ADE), and enhancing safety. Furthermore, it significantly improves humoral and cellular immunity.

The present invention provides a pharmaceutical formulation comprising a nucleic acid fragment, the nucleic acid fragment being mRNA, and comprising at least one of a first nucleic acid fragment, a second nucleic acid fragment, and a third nucleic acid fragment, wherein the first nucleic acid fragment encodes the M protein of feline infectious peritonitis virus, the second nucleic acid fragment encodes the N protein of feline infectious peritonitis virus, and the third nucleic acid fragment encodes the S, S_ec, or SII protein of feline infectious peritonitis virus, and the first and second nucleic acid fragments are or are not linked to the third nucleic acid fragment.